|
Biota Holdings Limited (ASX:BTA) Announce Completion of Enrolment In Phase II Clinical Study For Antiviral Influenza Treatment In Japan
Melbourne, Feb 11, 2008 (ABN Newswire) - Biota Holdings Limited (ASX: BTA) today announced that its long acting neuraminidase inhibitor (LANI), CS8958, an antiviral influenza treatment, has completed enrolment for its Phase II clinical study in Japan. The Phase II trial commencement was advised in an ASX Release on 22 November 2007.
Biota CEO, Peter Cook said "Early onset of the influenza season in Japan has assisted us in achieving rapid patient enrolment for this study. Enrolment admission to the study was always going to be a critical element in the length of this clinical trial".
About BIOTA HOLDINGS LIMITED
Biota is a leading anti-infective drug development company based in Melbourne Australia, with key expertise in respiratory diseases, particularly influenza. Biota developed the first-in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza.
Biota research breakthroughs have included a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease, licensed to MedImmune Inc. and novel nucleoside analogues designed to treat hepatitis C virus (HCV) infections, licensed to Boehringer Ingelheim. Biota has clinical trials underway with its lead compound for human rhinovirus (HRV) infection in patients with compromised respiration or immune systems. In addition, Biota has a key partnership with Daiichi-Sankyo for the development of second generation influenza antivirals. Inverness Medical markets Biota's co-developed OIA FLU influenza diagnostics.
Relenza(tm) is a registered trademark of the GlaxoSmithKline group of companies.
BioStar(R) OIA(R) FLU and BioStar(R) OIA(R) FLU A/B are registered trademarks of Inverness Medical.
*Further information available at www.biota.com.au.
|
|
|
